ORCID Profile
0000-0002-8338-9714
Current Organisation
Università Vita-Salute San Raffaele Facoltà di Medicina e Chirurgia
Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the Feedback Form.
Publisher: Public Library of Science (PLoS)
Date: 31-03-2015
Publisher: Oxford University Press (OUP)
Date: 25-01-2018
DOI: 10.1093/CID/CIX915
Publisher: Oxford University Press (OUP)
Date: 30-08-2016
DOI: 10.1093/CID/CIW519
Publisher: Wiley
Date: 26-06-2020
DOI: 10.1111/HIV.12888
Abstract: Although outcomes of antiretroviral therapy (ART) have been evaluated in randomized controlled trials, experiences from subpopulations defined by age, CD4 count or viral load (VL) in heterogeneous real‐world settings are limited. The study design was an international multicohort collaboration. Logistic regression was used to compare virological and immunological outcomes at 12 ± 3 months after starting ART with an integrase strand transfer inhibitor (INSTI), contemporary nonnucleoside reverse transcriptase inhibitor (NNRTI) or boosted protease inhibitor (PI/b) with two nucleos(t)ides after 1 January 2012. The composite treatment outcome (cTO) defined success as VL 200 HIV‐1 RNA copies/mL with no regimen change and no AIDS/death events. Immunological success was defined as a CD4 count 750 cells/μL or a 33% increase where the baseline CD4 count was ≥ 500 cells/μL. Poisson regression compared clinical failures (AIDS/death ≥ 14 days after starting ART). Interactions between ART class and age, CD4 count, and VL were determined for each endpoint. Of 5198 ART‐naïve persons in the International Cohort Consortium of Infectious Diseases (RESPOND), 45.4% started INSTIs, 26.0% PI/b and 28.7% NNRTIs 880 (17.4%) were aged 50 years, 2539 (49.4%) had CD4 counts 350 cells/μL and 1891 (36.8%) had VL 100 000 copies/mL. Differences in virological and immunological success and clinical failure among ART classes were similar across age groups (≤ 40, 40–50 and 50 years), CD4 count categories (≤ 350 vs. 350 cells/μL) and VL categories at ART initiation (≤ 100 000 vs. 100 000 copies/mL), with all investigated interactions being nonsignificant ( P 0.05). Differences among ART classes in virological, immunological and clinical outcomes in ART‐naïve participants were consistent irrespective of age, immune suppression or VL at ART initiation. While confounding by indication cannot be excluded, this provides reassuring evidence that such subpopulations will equally benefit from contemporary ART.
Publisher: Ovid Technologies (Wolters Kluwer Health)
Date: 14-01-2018
Publisher: Ovid Technologies (Wolters Kluwer Health)
Date: 03-2020
Publisher: Wiley
Date: 08-02-2019
DOI: 10.1111/HIV.12711
Abstract: The aim of the study was to establish a methodology for evaluating the hepatitis C continuum of care in HIV/hepatitis C virus (HCV)-coinfected in iduals and to characterize the continuum in Europe on 1 January 2015, prior to widespread access to direct-acting antiviral (DAA) therapy. Stages included in the continuum were as follows: anti-HCV antibody positive, HCV RNA tested, currently HCV RNA positive, ever HCV RNA positive, ever received HCV treatment, completed HCV treatment, follow-up HCV RNA test, and cure. Sustained virological response (SVR) could only be assessed for those with a follow-up HCV RNA test and was defined as a negative HCV RNA result measured > 12 or 24 weeks after stopping treatment. Numbers and percentages for the stages of the HCV continuum of care were as follows: anti-HCV positive (n = 5173), HCV RNA tested (4207 of 5173 81.3%), currently HCV RNA positive (3179 of 5173 61.5%), ever HCV RNA positive (n = 3876), initiated HCV treatment (1693 of 3876 43.7%), completed HCV treatment (1598 of 3876 41.2%), follow-up HCV RNA test to allow SVR assessment (1195 of 3876 30.8%), and cure (629 of 3876 16.2%). The proportion that achieved SVR was 52.6% (629 of 1195). There were significant differences between regions at each stage of the continuum (P < 0.0001). In the proposed HCV continuum of care for HIV/HCV-coinfected in iduals, we found major gaps at all stages, with almost 20% of anti-HCV-positive in iduals having no documented HCV RNA test and a low proportion achieving SVR, in the pre-DAA era.
Publisher: Elsevier BV
Date: 11-2015
Publisher: Springer Science and Business Media LLC
Date: 25-03-2014
Publisher: Public Library of Science (PLoS)
Date: 24-12-2009
Publisher: Wiley
Date: 11-2018
DOI: 10.1002/JIA2.25200
Publisher: Public Library of Science (PLoS)
Date: 09-09-2014
Location: Italy
No related grants have been discovered for antonella castagna.